Difference between revisions of "Ovarian cancer risk factors"

Jump to: navigation, search
(Overview)
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
 
{{Ovarian cancer}}
 
{{Ovarian cancer}}
{{CMG}}
+
{{CMG}}; {{AE}} {{Hudakarman}}
  
 
==Overview==
 
==Overview==

Revision as of 19:37, 12 July 2019

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer risk factors

CDC on Ovarian cancer risk factors

Ovarian cancer risk factors in the news

Blogs on Ovarian cancer risk factors

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.

Overview

The risk of developing ovarian cancer appears to be affected by several factors; in fact, early age at first pregnancy, older ages of final pregnancy, and the use of low dose hormonal contraception have been associated with a lower incidence of ovarian cancer. There is good evidence that in some women genetic factors are important.

Risk Factors

Known risk factors

There is convincing evidence that the following factors increase your risk of developing epithelial ovarian cancer and tumors of borderline malignancy.

Family history of ovarian cancer

  • Sometimes more cases of ovarian cancer develop in a family than would be expected by chance.
  • A family history of ovarian cancer means that one or more close blood relatives have or had ovarian cancer.
  • Sometimes it is not clear whether the family’s pattern of cancer is due to chance, shared lifestyle factors, a genetic risk passed from parents to children or a combination of these factors.
  • Having several relatives who have ovarian cancer can increase your risk of ovarian cancer. About 5%–10% of women with ovarian cancer have a family member who also has this disease.
  • Having relatives with ovarian cancer on either your mother’s or your father’s side of the family increases your risk.
  • The risk of developing ovarian cancer is increased if:
    • One first-degree relative (mother, sister or daughter) has ovarian cancer, especially if they were diagnosed with ovarian cancer before the age of 50 or before they went into menopause.
    • Women who have a mother diagnosed with ovarian cancer are at a higher risk than women who have a daughter diagnosed with ovarian cancer.
    • Two or more first-degree relatives have been diagnosed with ovarian cancer.
    • One first-degree relative and one second-degree relative (aunt, grandmother or niece) have been diagnosed with ovarian cancer. This combination means you have a slightly higher risk for ovarian cancer.

BRCA gene mutations

  • Only a small number of ovarian cancers (about 5%–10%) are related to a specific inherited genetic abnormality.
  • Breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2) normally help control the growth of cancer cells. BRCA gene mutations were first found in women with breast cancer. They also increase the risk of ovarian cancer.
  • These mutations can be inherited from either parent.
  • While mutations in BRCA1 or BRCA2 genes increase the risk of ovarian cancer, not all women with mutations in these genes will develop ovarian cancer.
  • Overall, BRCA1 increases the risk of ovarian cancer more than BRCA2.
  • Ovarian cancer is more likely to occur before age 50 in women with BRCA1 mutations.
  • Ovarian cancer is more likely to occur after age 60 in women with BRCA2 mutations.
  • BRCA gene mutations may be suspected in families if:
    • Ovarian cancer occurs in 3 or more first-degree relatives (mother, sisters or daughters).
    • Breast or ovarian cancer develops at a younger age in several first-degree relatives, including at least 2 relatives who have breast cancer and 2 who have ovarian cancer.
  • Ovarian cancers related to BRCA gene mutations are different from ovarian cancers in the general population of women (sporadic ovarian cancer). These cases of ovarian cancer are typically diagnosed at a younger age. The average age of diagnosis is 48 years for genetic forms, compared to 52 years for sporadic ovarian cancer.
  • Serous epithelial tumors are more commonly linked to BRCA gene mutations than sporadic forms of ovarian cancer
  • Having ovarian cancer linked to a BRCA gene mutation also increases the risk of developing papillary serous carcinoma of the peritoneum, which is cancer in the lining of the abdominal cavity. But there may be a more favorable prognosis for forms of the disease linked to BRCA gene mutations
  • Women with ovarian cancer related to a BRCA gene mutation are also at higher than average risk of developing breast and other cancers.
  • Genetic risk assessment and genetic testing may be an option for some women.

Lynch syndrome

  • Lynch syndrome (also called hereditary non-polyposis colorectal cancer, or HNPCC) is an uncommon genetic condition that increases the risk of colorectal and other cancers, including ovarian cancer
  • Women with type B Lynch syndrome, or Lynch II, have a higher risk of developing epithelial ovarian cancer in their lifetime.

Nullipara

  • Women who have never been pregnant have a higher risk of developing ovarian cancer than women who have been pregnant.
  • Researchers are not sure if the lower risk in women who have been pregnant is due to the hormones that are present during pregnancy, which may have a protective effect.
  • It is also unclear if the higher risk in women who have never been pregnant is linked to the factors that may make it difficult for her to become pregnant.
  • The risk for ovarian cancer is also higher in women who have never given birth (nulliparous), whether or not they have ever been pregnant.
  • Researchers are not sure if this increased risk is related to the same factors that increase the risk of ovarian cancer in women who have never been pregnant.

Family history of certain cancers

  • Women who have a family history of breast cancer have a higher risk of developing ovarian cancer.
  • A strong family history of uterine cancer, colon cancer, or other gastrointestinal cancers may indicate the presence of a syndrome known as hereditary nonpolyposis colorectal cancer (HNPCC, also known as Lynch II syndrome), which confers a higher risk for developing ovarian cancer.

Personal history of breast cancer

  • Women who have been diagnosed with breast cancer have a higher risk of developing ovarian cancer.
  • This could be because of a BRCA gene mutation.
  • Some of the same risk factors for breast cancer that are related to a woman's menstruation history may also increase her risk of developing ovarian cancer.
  • These risk factors include starting your period at an early age (younger than 11) or starting menopause at a later age (after age 55).

Ashkenazi Jewish ancestry

  • Studies have shown that women of Ashkenazi Jewish descent (Eastern European ancestry) are more likely than women in the general population to carry mutations of the BRCA1 and BRCA2 genes.
  • About 1 in 40 Ashkenazi Jewish women carry a BRCA gene mutation, while 1 in 500 women in the general population have the gene mutation.
  • Women with these mutations have a higher chance of developing ovarian cancer.

Hormone replacement therapy

  • Hormone replacement therapy (HRT) is used to manage the symptoms of menopause, such as hot flashes, vaginal dryness and mood swings.
  • Research shows that using estrogen alone as HRT increases the risk of ovarian cancer.
  • This risk increases with the length of time that the woman takes estrogen.
  • It is not clear if HRT that uses both estrogen and progestin (combined HRT) increases the risk for ovarian cancer.

Smoking

  • Smoking increases a woman’s risk of developing mucinous epithelial tumors of the ovary.

Asbestos

  • Studies have found that women who are heavily exposed to asbestos, especially in the workplace, are at an increased risk of developing ovarian cancer.
  • Other studies have shown that asbestos fibers can accumulate in the ovaries of women exposed to it.

Possible risk factors

  • The following factors have been linked with ovarian cancer, but there is not enough evidence to say they are known risk factors. Further study is needed to clarify the role of these factors for ovarian cancer.

Being obese

  • Being obese means having a body mass index, or BMI, of 30 or more.
  • Some studies have shown that being obese may slightly increase the risk of developing ovarian cancer.

Using talc on the genitals

  • Research studies on the use of talc on the genital, or perineal, area and the risk of ovarian cancer have had mixed results. Some studies show an increased risk, while others do not.
  • Some research suggests that in the past certain sources of talcum powder may have been contaminated with asbestos or may have contained asbestiform fibers which have similar properties as asbestos.
  • Health Canada now ensures that talcum powder does not contain asbestos. Talcum powders made with cornstarch do not increase the risk of ovarian cancer.

Endometriosis

  • Endometriosis occurs when the lining of the uterus (endometrium) grows outside of the uterus.
  • It can grow on the ovaries, behind the uterus or on the intestines (bowels) or bladder.
  • A recent Canadian study suggested that ovarian cancer and endometriosis may have a similar origin.
  • Other studies have suggested that a woman’s risk of developing ovarian cancer may be higher if she has endometriosis, especially if the endometriosis involves the ovaries.
  • Other studies have shown that the risk of certain types of ovarian cancer, including clear cell and endometrioid tumors, may be higher in women with endometriosis.

Tall adult height

  • Studies have shown that tall women have a slightly higher risk of ovarian cancer.
  • Researchers think this increased risk may be due to growth and puberty hormones, rather than being tall by itself.

References

  1. 1.0 1.1 Gates MA, Rosner BA, Hecht JL, Tworoger SS (2010). "Risk factors for epithelial ovarian cancer by histologic subtype". Am J Epidemiol. 171 (1): 45–53. doi:10.1093/aje/kwp314. PMC 2796984. PMID 19910378.
  2. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K; et al. (2011). "Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition". Br J Cancer. 105 (9): 1436–42. doi:10.1038/bjc.2011.371. PMC 3241548. PMID 21915124.
  3. Stewart LM, Holman CD, Aboagye-Sarfo P, Finn JC, Preen DB, Hart R (2013). "In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk". Gynecol Oncol. 128 (2): 260–4. doi:10.1016/j.ygyno.2012.10.023. PMID 23116937.
  4. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER (2001). "Menstrual and reproductive factors in relation to ovarian cancer risk". Br J Cancer. 84 (5): 714–21. doi:10.1054/bjoc.2000.1596. PMC 2363792. PMID 11237375.
  5. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE; et al. (2004). "Ovarian cancer risk associated with varying causes of infertility". Fertil Steril. 82 (2): 405–14. doi:10.1016/j.fertnstert.2004.02.109. PMID 15302291.
  6. 6.0 6.1 Bristow RE, Karlan BY (1996). "Ovulation induction, infertility, and ovarian cancer risk". Fertil Steril. 66 (4): 499–507. PMID 8816606.
  7. Erzen M, Rakar S, Klancnik B, Syrjänen K, Klancar B (2001). "Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study". Gynecol Oncol. 83 (1): 100–8. doi:10.1006/gyno.2001.6382. PMID 11585420.
  8. Barry JA, Azizia MM, Hardiman PJ (2014). "Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis". Hum Reprod Update. 20 (5): 748–58. doi:10.1093/humupd/dmu012. PMC 4326303. PMID 24688118.
  9. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M; et al. (2003). "Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial". JAMA. 290 (13): 1739–48. doi:10.1001/jama.290.13.1739. PMID 14519708.
  10. Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L; et al. (2008). "Hormone replacement therapy and ovarian cancer risk: a meta-analysis". Gynecol Oncol. 108 (3): 641–51. doi:10.1016/j.ygyno.2007.12.003. PMID 18221779.
  11. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE (2007). "Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk". Am J Epidemiol. 166 (8): 894–901. doi:10.1093/aje/kwm157. PMID 17656616.
  12. Chen S, Parmigiani G (2007). "Meta-analysis of BRCA1 and BRCA2 penetrance". J Clin Oncol. 25 (11): 1329–33. doi:10.1200/JCO.2006.09.1066. PMC 2267287. PMID 17416853.
  13. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H; et al. (2005). "BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases". Cancer. 104 (12): 2807–16. doi:10.1002/cncr.21536. PMID 16284991.
  14. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H; et al. (2005). "BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases". Cancer. 104 (12): 2807–16. doi:10.1002/cncr.21536. PMID 16284991.
  15. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S; et al. (2004). "Pathology of ovarian cancers in BRCA1 and BRCA2 carriers". Clin Cancer Res. 10 (7): 2473–81. PMID 15073127.
  16. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY; et al. (2012). "Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer". JAMA. 307 (4): 382–90. doi:10.1001/jama.2012.20. PMC 3727895. PMID 22274685.
  17. Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F; et al. (2003). "Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations". J Clin Oncol. 21 (22): 4222–7. doi:10.1200/JCO.2003.04.131. PMID 14615451.
  18. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR; et al. (1998). "BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing". Am J Obstet Gynecol. 178 (4): 670–7. doi:10.1016/s0002-9378(98)70476-4. PMID 9579428.
  19. Kauff ND, Mitra N, Robson ME, Hurley KE, Chuai S, Goldfrank D; et al. (2005). "Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families". J Natl Cancer Inst. 97 (18): 1382–4. doi:10.1093/jnci/dji281. PMID 16174860.
  20. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA; et al. (2011). "Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer". Gynecol Oncol. 121 (2): 353–7. doi:10.1016/j.ygyno.2011.01.020. PMID 21324516.
  21. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S; et al. (2016). "Inherited Mutations in Women With Ovarian Carcinoma". JAMA Oncol. 2 (4): 482–90. doi:10.1001/jamaoncol.2015.5495. PMC 4845939. PMID 26720728.
  22. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM (2006). "Does smoking increase risk of ovarian cancer? A systematic review". Gynecol Oncol. 103 (3): 1122–9. doi:10.1016/j.ygyno.2006.08.012. PMID 17005245.
  23. Huncharek M, Geschwind JF, Kupelnick B (2003). "Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies". Anticancer Res. 23 (2C): 1955–60. PMID 12820486.
  24. Blank MM, Wentzensen N, Murphy MA, Hollenbeck A, Park Y (2012). "Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study". Br J Cancer. 106 (3): 596–602. doi:10.1038/bjc.2011.572. PMC 3273348. PMID 22223086.
  25. Carnide N, Kreiger N, Cotterchio M (2009). "Association between frequency and intensity of recreational physical activity and epithelial ovarian cancer risk by age period". Eur J Cancer Prev. 18 (4): 322–30. doi:10.1097/CEJ.0b013e32832bf3fa. PMID 19390450.
  26. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003). "Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults". N Engl J Med. 348 (17): 1625–38. doi:10.1056/NEJMoa021423. PMID 12711737.
  27. Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ; et al. (2011). "Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study". Lancet Oncol. 12 (9): 900–4. doi:10.1016/S1470-2045(11)70165-6. PMID 21835693.

Linked-in.jpg